Vanguard Group Inc. Decreases Stake in Repligen Corporation (NASDAQ:RGEN)

Vanguard Group Inc. lowered its position in shares of Repligen Corporation (NASDAQ:RGEN) by 0.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,079,894 shares of the biotechnology company’s stock after selling 21,196 shares during the quarter. Vanguard Group Inc. owned about 9.05% of Repligen worth $646,366,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. KBC Group NV grew its holdings in shares of Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 329 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in shares of Repligen during the 1st quarter worth about $132,000. GAMMA Investing LLC grew its holdings in shares of Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 274 shares during the period. XTX Topco Ltd lifted its position in Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock worth $1,646,000 after acquiring an additional 3,295 shares in the last quarter. Finally, TD Asset Management Inc lifted its position in Repligen by 10.9% during the 1st quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company’s stock worth $6,511,000 after acquiring an additional 5,014 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $127.15 on Thursday. The business’s 50 day moving average is $122.58 and its two-hundred day moving average is $133.62. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of -508.58, a PEG ratio of 2.23 and a beta of 1.05. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period in the previous year, the company earned $0.40 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Royal Bank Of Canada boosted their price target on Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 30th. Wells Fargo & Company reduced their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Finally, Barclays initiated coverage on Repligen in a research report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.